Details of Disease

Disease Name

Intracranial meningioma

brain meningioma; brain meningioma; meningioma (disease) of brain

Definition

A meningioma that arises within the cranial cavity.

Disease Hierarchy

DISPT4TG: Meningioma

DISD09EF: Intracranial meningioma

Disease Identifiers

MONDO ID

MONDO_0850302

MESH ID

D008579

UMLS CUI

C0349604

MedGen ID

83891

HPO ID

HP:0100009

SNOMED CT ID

302820008

General Information of Disease (ID: DISD09EF)

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 3 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Bevacizumab	DMSD1UN	Approved	Monoclonal antibody	[1]
Everolimus	DM8X2EH	Approved	Small molecular drug	[2]
Sirolimus	DMGW1ID	Approved	Small molecular drug	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 7 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ALAD	TTJHKYD	Limited	Biomarker	[4]
AKT1	TTWTSCV	Strong	Biomarker	[5]
CTSL	TT36ETB	Strong	Biomarker	[6]
PGR	TTUV8G9	Strong	Biomarker	[6]
PTEN	TTXJ3W7	Strong	Biomarker	[7]
SMO	TT8J1S3	Strong	Biomarker	[5]
NF2	TTZIK7P	Definitive	Biomarker	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 DTT(s)

This Disease Is Related to 7 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ARMC5	OTO7IV74	Strong	Genetic Variation	[8]
CEBPZ	OT11BATG	Strong	Biomarker	[9]
CST3	OTNZ6AO4	Strong	Biomarker	[6]
CSTB	OT3U0JF8	Strong	Biomarker	[6]
HES1	OT8P19W2	Strong	Biomarker	[10]
MLLT10	OTURMDV7	Strong	Biomarker	[11]
SMARCB1	OT2LP7LJ	Strong	Genetic Variation	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 DOT(s)

References

1	The controversial role of Bevacizumab in the treatment of patients with intracranial meningioma: a comprehensive literature review. Expert Rev Anticancer Ther. 2020 Mar;20(3):197-203.
2	Everolimus FDA Label
3	Sirolimus FDA Label
4	Delta-aminolevulinic acid dehydratase polymorphism and risk of brain tumors in adults. Environ Health Perspect. 2005 Sep;113(9):1209-11.
5	Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations.Nat Genet. 2013 Mar;45(3):285-9. doi: 10.1038/ng.2526. Epub 2013 Jan 20.
6	Toward understanding recurrent meningioma: the potential role of lysosomal cysteine proteases and their inhibitors.J Neurosurg. 2010 May;112(5):940-50. doi: 10.3171/2009.7.JNS081729.
7	A novel germline mutation of PTEN associated with brain tumours of multiple lineages.Br J Cancer. 2002 May 20;86(10):1586-91. doi: 10.1038/sj.bjc.6600206.
8	Molecular and clinical evidence for an ARMC5 tumor syndrome: concurrent inactivating germline and somatic mutations are associated with both primary macronodular adrenal hyperplasia and meningioma.J Clin Endocrinol Metab. 2015 Jan;100(1):E119-28. doi: 10.1210/jc.2014-2648.
9	Application of arterial spin labeling perfusion MRI to differentiate benign from malignant intracranial meningiomas.Eur J Radiol. 2017 Dec;97:31-36. doi: 10.1016/j.ejrad.2017.10.005. Epub 2017 Oct 7.
10	Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres.Genes Cancer. 2010 Aug;1(8):822-35. doi: 10.1177/1947601910383564.
11	Common variation at 10p12.31 near MLLT10 influences meningioma risk.Nat Genet. 2011 Jul 31;43(9):825-7. doi: 10.1038/ng.879.
12	Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria.Am J Med Genet A. 2013 Mar;161A(3):405-16. doi: 10.1002/ajmg.a.35760. Epub 2013 Feb 7.